Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry
In: Journal of pharmaceutical and biomedical analysis, Jg. 209 (2021-09-01)
Online
unknown
Zugriff:
The global transcription inhibitor terameprocol is being evaluated clinically as an oral formulation to treat high-grade glioma. A sensitive, reliable method was developed to quantitate terameprocol using LC-MS/MS to perform detailed pharmacokinetic studies. Sample preparation involved protein precipitation using acetonitrile. Separation of terameprocol and the internal standard, Sorafenib-methyl-d3, was achieved with a Zorbax XDB C18 column (2.1 × 50 mm, 3.5 μm) and gradient elution over a 2-minute total analytical run time. A SCIEX 4500 or SCIEX 5500 triple quadrupole mass spectrometer operated in positive electrospray ionization mode was used for terameprocol detection. The assay range of 5-1,000 ng/mL was demonstrated to be accurate (92.7-107.4%) and precise (CV ≤ 11.3%). A sample diluted 1:10 (v/v) was accurately quantitated. Terameprocol in plasma has been proven stable for at least 20 months when stored at −70°C. The method was applied to the measurement of total plasma concentrations of terameprocol in a patient with a high-grade glioma receiving a 300 mg oral dose.
Titel: |
Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry
|
---|---|
Autor/in / Beteiligte Person: | Anders, Nicole M. ; Romo, Carlos G. ; Hemingway, Avelina ; Ahluwalia, Manmeet S. ; Rudek, Michelle A. |
Link: | |
Zeitschrift: | Journal of pharmaceutical and biomedical analysis, Jg. 209 (2021-09-01) |
Veröffentlichung: | 2021 |
Medientyp: | unknown |
ISSN: | 1873-264X (print) |
Schlagwort: |
|
Sonstiges: |
|